GET DAILY SIGNALSAddus HomeCare (ADUS) Delivers 17.3% EPS Growth in Q3 Despite Narrow Revenue Miss
Key Takeaways
- Adjusted earnings per share (EPS) came in at $1.83, topping the $1.79 consensus estimate by $0.04 and rising 17.3% year over year.
- Net service revenue of $387.7 million grew 7.0% from a year earlier but landed slightly below the $388.70 million analysts had expected.
- GAAP net income reached $28.6 million, or $1.54 per diluted share, up from $22.8 million, or $1.24 per share, a year ago.
- Adjusted EBITDA climbed 13.5% to $51.2 million, underscoring improving operating leverage.
- Personal care, the company's largest segment at 77.6% of revenue, posted 6.9% organic growth, while hospice and home health also expanded.
- Shares slipped roughly 2.6% in after-hours trading as the modest revenue shortfall offset the earnings beat.
Why This Quarter Matters
ADUS is one of the largest U.S. providers of in-home personal care, hospice, and home health services, with revenue tied heavily to government reimbursement programs such as Medicaid and Medicare. Its third quarter 2026 report matters because it shows whether demand for aging-in-place care remains resilient and whether the company can convert that demand into margin expansion. The results arrive against a backdrop of consolidation, highlighted by ADUS's September 2026 agreement to acquire AccentCare's personal care division for roughly $275 million. Investors were watching whether organic growth held up ahead of that integration, making this quarter an important signal of the company's underlying momentum and cost discipline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
For the third quarter ended September 30, 2026, ADUS reported net service revenue of $387.7 million, an increase of 7.0% from $362.3 million in the prior-year period but narrowly below the $388.70 million consensus. GAAP net income rose to $28.6 million, or $1.54 per diluted share, compared with $22.8 million, or $1.24 per share, a year earlier.
On a non-GAAP basis, adjusted EPS climbed 17.3% year over year to $1.83, exceeding the $1.79 analyst estimate by $0.04. Adjusted EBITDA grew 13.5% to $51.2 million from $45.1 million, outpacing revenue growth and reflecting operating leverage. Cash flow from operations was $40.9 million for the quarter. From what I see, the margin improvement stands out as a positive sign of operating discipline.
By segment, personal care contributed 77.6% of revenue and posted 6.9% organic growth, supported by volume expansion and the HomeCourt Home Care acquisition. Hospice represented 17.8% of revenue with a 4.3% organic increase in average daily census, or 8.8% excluding a prior-year benefit. Home health, at 4.6% of revenue, returned to year-over-year organic growth.
Market Reaction and Investor Sentiment
ADUS shares closed at $126.20 and fell about 2.6% in after-hours trading following the release. The reaction reflected a mixed read: the adjusted EPS beat by $0.04 was overshadowed by revenue that came in slightly below consensus. With the stock up more than 12% over the prior twelve months, investors appeared focused on whether top-line momentum could keep pace with the company's profitability gains. The modest revenue miss, though narrow, was enough to prompt some profit-taking, even as segment-level organic growth and margin expansion remained broadly healthy across personal care, hospice, and home health.
Forward Outlook and Key Factors to Monitor
The most significant catalyst ahead is the closing and integration of the AccentCare personal care division acquisition, announced in September 2026. The deal is expected to add roughly $280 million in annualized revenue, expanding the company's revenue base by nearly 19%, while strengthening its presence in Texas, Illinois, California, and Arizona. Investors will watch for the timing of regulatory approvals and any update on integration costs or synergy assumptions.
Beyond the acquisition, key factors to monitor include reimbursement rate trends across core states, the pace of organic census and billable-hour growth, and the sustainability of margin expansion as the company absorbs a larger workforce. Labor availability and caregiver hiring costs remain central to profitability in a business driven by personal care hours.
Home health volumes, which have been more volatile, will also be worth tracking as management works to sustain the segment's return to organic growth. As always with ADUS, government payment policy and state-level Medicaid dynamics can shift demand and pricing, making reimbursement updates an ongoing watch item for the quarters ahead. I’m watching this closely as the integration unfolds.
AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when digging into healthcare providers like this. The tool helps me quickly scan for comparable names using growth metrics, technical patterns, and AI signals, which adds useful context when evaluating quarterly results and peer performance. It has become a regular part of how I cross-check ideas without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ADUS in upward trend: 10-day moving average broke above 50-day moving average on October 22, 2026
The 10-day moving average for ADUS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on ADUS as a result. In 59 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for ADUS just turned positive on October 08, 2026. Looking at past instances where ADUS's MACD turned positive, the stock continued to rise in 32 of 46 cases over the following month. The odds of a continued upward trend are 70%.
ADUS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADUS advanced for three days, in 204 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 142 of 218 cases where ADUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
ADUS broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ADUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.045) is normal, around the industry mean (204.027). P/E Ratio (21.681) is within average values for comparable stocks, (19.383). Projected Growth (PEG Ratio) (0.983) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.092) among similar stocks. P/S Ratio (1.483) is also within normal values, averaging (2.688).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What are Alternative Funds?
What are the Expenses Associated with Buying and Owning Mutual Funds?
What is Diminishing Marginal Utility?
AI Trading Delivers strong performance Amid Shale Volatility (FANG, COP, EOG, HAL)
Retail Panic Hits a 20-Year Extreme: The ROBO Put/Call Ratio Is Flashing a Massive Contrarian Signal
General Information
a provider of home and community based services
Industry HospitalNursingManagement
Advertisement